179 related articles for article (PubMed ID: 36682681)
1. Hydroxychloroquine for pre-exposure prophylaxis of COVID-19 in health care workers: a randomized, multicenter, placebo-controlled trial Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine (HERO-HCQ).
Naggie S; Milstone A; Castro M; Collins SP; Lakshmi S; Anderson DJ; Cahuayme-Zuniga L; Turner KB; Cohen LW; Currier J; Fraulo E; Friedland A; Garg J; George A; Mulder H; Olson RE; O'Brien EC; Rothman RL; Shenkman E; Shostak J; Woods CW; Anstrom KJ; Hernandez AF;
Int J Infect Dis; 2023 Apr; 129():40-48. PubMed ID: 36682681
[TBL] [Abstract][Full Text] [Related]
2. ChemoPROphyLaxIs with hydroxychloroquine For covId-19 infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers: A structured summary of a study protocol for a randomised controlled trial.
McEniery CM; Fisk M; Miles K; Kaloyirou F; Hubsch A; Smith J; Wilkinson IB; Cheriyan J
Trials; 2020 Jul; 21(1):604. PubMed ID: 32616067
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
Barnabas RV; Brown E; Bershteyn A; Miller RS; Wener M; Celum C; Wald A; Chu H; Wesche D; Baeten JM;
Trials; 2020 Jun; 21(1):475. PubMed ID: 32493478
[TBL] [Abstract][Full Text] [Related]
4. Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial.
González R; García-Otero L; Pons-Duran C; Marbán-Castro E; Goncé A; Llurba E; Gil MDM; Rodríguez-Zambrano MÁ; Chen H; Ramírez M; Bardají A; Menendez C
Trials; 2020 Jul; 21(1):607. PubMed ID: 32616063
[TBL] [Abstract][Full Text] [Related]
5. Hydroxychloroquine in the treatment of adult patients with Covid-19 infection in a primary care setting (LIBERTY): A structured summary of a study protocol for a randomised controlled trial.
Vainio PJ; Hietasalo P; Koivisto AL; Kääriäinen S; Turunen J; Virtala M; Vuorinen J; Scheinin M
Trials; 2021 Jan; 22(1):44. PubMed ID: 33430933
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial.
Abella BS; Jolkovsky EL; Biney BT; Uspal JE; Hyman MC; Frank I; Hensley SE; Gill S; Vogl DT; Maillard I; Babushok DV; Huang AC; Nasta SD; Walsh JC; Wiletyo EP; Gimotty PA; Milone MC; Amaravadi RK;
JAMA Intern Med; 2021 Feb; 181(2):195-202. PubMed ID: 33001138
[TBL] [Abstract][Full Text] [Related]
7. Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo-controlled randomized trial in healthcare workers.
Polo R; García-Albéniz X; Terán C; Morales M; Rial-Crestelo D; Garcinuño MA; García Del Toro M; Hita C; Gómez-Sirvent JL; Buzón L; Díaz de Santiago A; Arellano JP; Sanz J; Bachiller P; Alfaro EM; Díaz-Brito V; Masiá M; Hernández-Torres A; Guerra JM; Santos J; Arazo P; Muñoz L; Arribas JR; Martínez de Salazar P; Moreno S; Hernán MA; Del Amo J;
Clin Microbiol Infect; 2023 Jan; 29(1):85-93. PubMed ID: 35940567
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of hydroxychloroquine as prophylactic against COVID-19 in healthcare workers: a meta-analysis of randomised clinical trials.
Hong H; Friedland A; Hu M; Anstrom KJ; Halabi S; McKinnon JE; Amaravadi R; Rojas-Serrano J; Abella BS; Portillo-Vázquez AM; Woods CW; Hernandez AF; Boulware DR; Naggie S; Rajasingham R
BMJ Open; 2023 Jun; 13(6):e065305. PubMed ID: 37328184
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
10. Safety and tolerability of hydroxychloroquine in health care workers and first responders for the prevention of COVID-19: WHIP COVID-19 Study.
McKinnon JE; Wang DD; Zervos M; Saval M; Marshall-Nightengale L; Kilgore P; Pabla P; Szandzik E; Maksimowicz-McKinnon K; O'Neill WW
Int J Infect Dis; 2022 Mar; 116():167-173. PubMed ID: 34954095
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of hydroxychloroquine for treatment of mild SARS-CoV-2 infection and prevention of COVID-19 severity in pregnant and postpartum women: A randomized, double-blind, placebo-controlled trial.
González R; Goncé A; Gil MDM; Mazarico E; Ferriols-Pérez E; Toro P; Llurba E; Saéz E; Rodríguez-Zambrano MÁ; García-Otero L; López M; Santacruz B; Román MÁ; Payà A; Alonso S; Cruz-Lemini M; Pons-Duran C; Herrera LB; Chen H; Bardají A; Quintó L; Menendez C;
Acta Obstet Gynecol Scand; 2024 Mar; 103(3):602-610. PubMed ID: 38098221
[TBL] [Abstract][Full Text] [Related]
12. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
[TBL] [Abstract][Full Text] [Related]
13. Pre-exposure prophylaxis with hydroxychloroquine for COVID-19: a double-blind, placebo-controlled randomized clinical trial.
Grau-Pujol B; Camprubí-Ferrer D; Marti-Soler H; Fernández-Pardos M; Carreras-Abad C; Andrés MV; Ferrer E; Muelas-Fernandez M; Jullien S; Barilaro G; Ajanovic S; Vera I; Moreno L; Gonzalez-Redondo E; Cortes-Serra N; Roldán M; Arcos AA; Mur I; Domingo P; Garcia F; Guinovart C; Muñoz J
Trials; 2021 Nov; 22(1):808. PubMed ID: 34781981
[TBL] [Abstract][Full Text] [Related]
14. Design of the Healthcare Worker Exposure Response and Outcomes (HERO) research platform.
Friedland A; Hernandez AF; Anstrom KJ; Chen-Lim ML; Cohen LW; Currier JS; Forrest CB; Fraser R; Fraulo E; George A; Handberg E; Jackman J; Koellhoffer J; Lawrence D; Leverty R; McAdams P; McCourt B; Mickley B; Naqvi SH; O'Brien EC; Olson R; Prater C; Rothman RL; Shenkman E; Shostak J; Turner KB; Webb L; Woods C; Naggie S;
Contemp Clin Trials; 2021 Oct; 109():106525. PubMed ID: 34371163
[TBL] [Abstract][Full Text] [Related]
15. Why is pre-exposure prophylaxis with hydroxychloroquine a safe and rationale approach against SARS-CoV-2 infection?
Mehta S; Bhandari S; Mehta S
J Glob Antimicrob Resist; 2020 Sep; 22():864-865. PubMed ID: 32777441
[TBL] [Abstract][Full Text] [Related]
16. Safety of hydroxychloroquine in healthcare workers for COVID-19 prophylaxis.
Faruqui AR; Xavier D; Kamat SK; Chandy SJ; Medhi B; Tripathi RK; Shetty YC; Raj JM; Kaushal S; Balakrishnan S; Atal S; Tripathi SK; Badyal DK; Dikshit H; Roy SS; Trivedi N; Chatterjee S; Desai C; Tripathi CD; Rege NN; Gupta P; Raveendran R; Kaul R; Kshirsagar NA
Indian J Med Res; 2021 Jan & Feb; 153(1 & 2):219-226. PubMed ID: 33818480
[TBL] [Abstract][Full Text] [Related]
17. Hydroxychloroquine as Pre-exposure Prophylaxis for Coronavirus Disease 2019 (COVID-19) in Healthcare Workers: A Randomized Trial.
Rajasingham R; Bangdiwala AS; Nicol MR; Skipper CP; Pastick KA; Axelrod ML; Pullen MF; Nascene AA; Williams DA; Engen NW; Okafor EC; Rini BI; Mayer IA; McDonald EG; Lee TC; Li P; MacKenzie LJ; Balko JM; Dunlop SJ; Hullsiek KH; Boulware DR; Lofgren SM;
Clin Infect Dis; 2021 Jun; 72(11):e835-e843. PubMed ID: 33068425
[TBL] [Abstract][Full Text] [Related]
18. Hydroxychloroquine pre-exposure prophylaxis provides no protection against COVID-19 among health care workers: a cross-sectional study in a tertiary care hospital in North India.
Juneja S; Rana P; Chawla P; Katoch R; Singh K; Rana S; Mittal T; Kaur B; Kaur S
J Basic Clin Physiol Pharmacol; 2022 Jan; 33(1):103-107. PubMed ID: 34995022
[TBL] [Abstract][Full Text] [Related]
19. Hydroxychloroquine to prevent SARS-CoV-2 infection among healthcare workers: early termination of a phase 3, randomised, open-label, controlled clinical trial.
Llanos-Cuentas A; Schwalb A; Quintana JL; Delfin B; Alvarez F; Ugarte-Gil C; Guerra Gronerth RI; Lucchetti A; Grogl M; Gotuzzo E
BMC Res Notes; 2023 Feb; 16(1):22. PubMed ID: 36849996
[TBL] [Abstract][Full Text] [Related]
20. Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection : A Randomized Trial.
Barnabas RV; Brown ER; Bershteyn A; Stankiewicz Karita HC; Johnston C; Thorpe LE; Kottkamp A; Neuzil KM; Laufer MK; Deming M; Paasche-Orlow MK; Kissinger PJ; Luk A; Paolino K; Landovitz RJ; Hoffman R; Schaafsma TT; Krows ML; Thomas KK; Morrison S; Haugen HS; Kidoguchi L; Wener M; Greninger AL; Huang ML; Jerome KR; Wald A; Celum C; Chu HY; Baeten JM;
Ann Intern Med; 2021 Mar; 174(3):344-352. PubMed ID: 33284679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
